Table 3.
Marginal willingness-to-pay (WTP) estimates across surveys (in Australian $).
| Pediatric | Symptomatic adult | At-risk adult | |
|---|---|---|---|
| Mean (95% CIs) | Mean (95% CIs) | Mean (95% CIs) | |
| Chance of having a genetic condition (%)a | 57 (42 to 72) | 29 (23 to 35) | 32 (24 to 40) |
| Severity of the condition (moderate)b | 1325 (806 to 1843) | 692 (368 to 1015) | 490 (218 to 762) |
| Severity of the condition (severe)b | 2860 (2230 to 3490) | 1670 (1230 to 2042) | 882 (562 to 1203) |
| Availability of preventive or treatment options (improve condition)c | 3580 (2915 to 4245) | 2422 (2049 to 2794) | 2209 (1846 to 2573) |
| Availability of preventive or treatment options (cure/prevent condition)c | 4800 (4014 to 5583) | 3043 (2634 to 3452) | 2972 (2592 to 3352) |
| Improving the process of medical care (somewhat likely)d | 1790 (1231 to 2350) | 1152 (824 to 1480) | 1011 (730 to 1292) |
| Improving the process of medical care (very likely)d | 2340 (1675 to 3005) | 1625 (1262 to 1986) | 1177 (869 to 1485) |
| Disclosure of test results to otherse | −520 (−965 to −75) | −690 (−948 to −428) | −378 (−571 to −184) |
| Disclosure of secondary findings to youf | 1045 (503 to 1586) | 302 (38 to 566) | 567 (310 to 826) |
CI confidence interval.
aThe additional value that participants would be willing to pay on average for genomic sequencing (GS) for every percentage point increase in the chance of having a genetic condition.
bThe additional value that participants would be willing to pay on average for GS if the condition was moderate or severe relative to mild.
cThe additional value that participants would be willing to pay on average for GS if there were available preventive or treatment options.
dThe additional value that participants would be willing to pay on average for GS if it was somewhat likely or very likely to improve the process of care instead of unlikely.
eThe value that participants would be willing to pay on average to avoid a potential disclosure of their test results to a life insurer.
fThe value that participants would be willing to pay on average to find out about secondary findings from GS.